Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a Roche exclusive target. This has triggered a milestone payment under the agreement.

Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fourth biologic target selected by Roche.

"Roche and Halozyme have successfully completed the necessary drug product formulation and preclinical studies required to initiate a clinical trial. Entering the clinic is a significant achievement and demonstrates Roche's strong commitment to a successful partnership," said Jonathan Lim, M.D., Halozyme's President and CEO. "We are very pleased with the progress that is being made through our collaboration. Roche is a global leader in the development of biologics and we are excited that they have selected a fourth exclusive target, in addition to the three already under development, further validating Halozyme's core technology."

Roche has also maintained its rights to other targets covered in the license and collaboration agreement. An aggregate payment of $10.25 million will be made to Halozyme for commencing a Phase 1 clinical trial, exercising exclusive global rights to a fourth biologic target and for annual maintenance fees.

Halozyme also announced that it has entered into a supply agreement with Roche to provide rHuPH20 for use in formu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... update and reported financial results for the second ... "We have continued to see encouraging advancements in ... quarter-over-quarter increase in estimated total prescriptions and estimated ... said Jack Lief, Arena,s President and Chief Executive ...
(Date:7/31/2014)... 2014 Cipla Europe ... bekannt, vor kurzem für OneDose ReadyfusOR™ von ... chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen zu ... und weiterer europäischer Länder abdeckt. Cipla plant, ... gefüllte OneDose ReadyfusOR später in diesem Jahr ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
... Calif., July 31, 2011 Accuray Incorporated ... radiation oncology company, announced today that it will showcase ... TomoTherapy® Radiation Therapy Treatment System in the ... Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical ...
Cached Medicine Technology:Insulin- Western Europe 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 3Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 4
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Patients with the progressive, ... (COPD) have a new weapon to battle the disease, ... The agency approved a new treatment, an inhaled ... leading killer of Americans. COPD, which is often linked ... bronchitis and emphysema. Patients with COPD may ...
(Date:8/1/2014)... According to new market research report ... America, Europe, & ROW), by Vehicle Type (Passenger ... & Diesel), by After-Treatment Device (DPF, DOC, SCR, ... to 2019", defines and segments the global automotive ... countries in all the regions, and estimates their ...
(Date:8/1/2014)... Over the past five years, ... technologies that have enabled cosmetic dentists to provide ... Moreover, the burgeoning elderly population has stimulated demand ... Due to long-term use of medications, which may ... dental fillings, veneers and implants. As more elderly ...
(Date:8/1/2014)... Albany, NY (PRWEB) August 01, 2014 ... Surgical Generators Market Outlook to 2020", provides ... Surgical Generators market. The report provides value, ... units) and average prices (in US dollars) ... Electrocautery Generators, Ultrasonic Generators and Argon Plasma ...
Breaking Medicine News(10 mins):Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... Dr. Hungerford is ... invasive single as well as double hip replacement procedures. , ... (Vocus) June 29, 2009 -- Noted orthopedic surgeon Marc ... hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. Thomas Whitten, Chief of Orthopedics at ...
... the victims of these falls, CDC says , MONDAY, ... 47,000 elderly Americans are treated at hospital emergency departments ... according to a federal government study released Monday. , ... day. , U.S. Centers for Disease Control and Prevention ...
... the 1600s quinine was the first effective treatment in the ... commonly used treatment against this devastating disease. But the drug ... can range from sickness and headaches to blindness, deafness and ... knew why. Scientists at The University of Nottingham have ...
... emergency departments first sites for savings ... CalRHIO announced today that it has selected the RAND ... measure savings resulting from physicians having secure electronic access to ... The first phase of the initiative will measure savings in ...
... N.C., June 29 Carolinas HealthCare System ... growth and development of cardiovascular services in North and South ... Sanger Heart and Vascular Institute (SHVI) represents a ... and Vascular Institute. The Institute will continue serving as a ...
... Medicaid Funding Boost Merely Scratches Surface in Terms of Meeting ... In summing up the 2009 session of the Texas ... by Governor Rick Perry, the Texas Health Care Association (THCA) ... ($60 million general revenue) for Medicaid-financed nursing home care, substantially ...
Cached Medicine News:Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:47,000 Elderly Hurt in Walker, Cane Mishaps Each Year 2Health News:Breakthrough in combating the side effects of quinine 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2
... Efficient operation in the cath lab ... the daily clinical routine as cardiologists ... care and lower costs. With AXIOM ... recording system that helps to master ...
... Siemens introduces the AXIOM Artis ... first biplane magnetic navigation system equipped ... both planes, which is uniquely capable ... of catheter-based procedures to facilitate increased ...
... AXIOM Artis dTC is a versatile solution ... cardiology department from preparation to diagnosis ... procedures. With AXIOM Artis dTC, your cath ... cardiology department that leaves you free to ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
Medicine Products: